{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T17:00:42Z","timestamp":1784912442917,"version":"3.55.0"},"reference-count":213,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci. China Life Sci."],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11427-025-3227-0","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:54:15Z","timestamp":1778230455000},"page":"2657-2675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Decoding immunotherapy resistance in multiple myeloma: genetic insights and approaches to counter resistance"],"prefix":"10.1007","volume":"69","author":[{"given":"Huan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialing","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengzi","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingze","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"3227_CR1","doi-asserted-by":"crossref","unstructured":"(2019). BiTE therapy active in multiple myeloma. Cancer Discov 9, 157\u2013158.","DOI":"10.1158\/2159-8290.CD-NB2019-001"},{"key":"3227_CR2","doi-asserted-by":"crossref","unstructured":"(2023). MonumenTAL results for talquetamab in myeloma. Cancer Discov 13, 250\u2013251.","DOI":"10.1158\/2159-8290.CD-NB2022-0079"},{"key":"3227_CR3","doi-asserted-by":"publisher","first-page":"1411352","DOI":"10.3389\/fimmu.2024.1411352","volume":"15","author":"P Abdollahi","year":"2024","unstructured":"Abdollahi, P., Norseth, H.M., and Schjesvold, F. (2024). Advances and challenges in anti-cancer vaccines for multiple myeloma. Front Immunol 15, 1411352.","journal-title":"Front Immunol"},{"key":"3227_CR4","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1177\/1060028016642786","volume":"50","author":"S Afifi","year":"2016","unstructured":"Afifi, S., Michael, A., and Lesokhin, A. (2016). Immunotherapy. Ann Pharmacother 50, 555\u2013568.","journal-title":"Ann Pharmacother"},{"key":"3227_CR5","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1200\/JCO.2022.40.16_suppl.3001","volume":"40","author":"RR Aggarwal","year":"2022","unstructured":"Aggarwal, R.R., Vuky, J., VanderWeele, D.J., Rettig, M., Heath, E.I., Beer, T.M., Huang, J., Pawlowska, N., Sinit, R., Abbey, J., et al. (2022). Phase 1a\/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 40, 3001.","journal-title":"J Clin Oncol"},{"key":"3227_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41408-024-00986-z","volume":"14","author":"R Ajore","year":"2024","unstructured":"Ajore, R., Mattsson, J., Pertesi, M., Ekdahl, L., Ali, Z., Hansson, M., and Nilsson, B. (2024). Genome-wide CRISPR\/Cas9 screen identifies regulators of BCMA expression on multiple myeloma cells. Blood Cancer J 14, 21.","journal-title":"Blood Cancer J"},{"key":"3227_CR7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.clml.2016.06.006","volume":"16","author":"A Alemu","year":"2016","unstructured":"Alemu, A., Richards, J.O., Oaks, M.K., and Thompson, M.A. (2016). Vaccination in multiple myeloma: review of current literature. Clin Lymphoma Myeloma Leuk 16, 495\u2013502.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3227_CR8","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1038\/s41375-021-01127-2","volume":"35","author":"K Alhallak","year":"2021","unstructured":"Alhallak, K., Sun, J., Wasden, K., Guenthner, N., O\u2019Neal, J., Muz, B., King, J., Kohnen, D., Vij, R., Achilefu, S., et al. (2021). Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy. Leukemia 35, 2346\u20132357.","journal-title":"Leukemia"},{"key":"3227_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12943-023-01736-8","volume":"22","author":"A Andrades","year":"2023","unstructured":"Andrades, A., Peinado, P., Alvarez-Perez, J.C., Sanjuan-Hidalgo, J., Garc\u00eda, D.J., Arenas, A.M., Matia-Gonz\u00e1lez, A.M., and Medina, P.P. (2023). SWI\/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities. Mol Cancer 22, 39.","journal-title":"Mol Cancer"},{"key":"3227_CR10","doi-asserted-by":"publisher","first-page":"e150807","DOI":"10.1172\/JCI150807","volume":"132","author":"S Arcangeli","year":"2022","unstructured":"Arcangeli, S., Bove, C., Mezzanotte, C., Camisa, B., Falcone, L., Manfredi, F., Bezzecchi, E., El Khoury, R., Norata, R., Sanvito, F., et al. (2022). CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. J Clin Invest 132, e150807.","journal-title":"J Clin Invest"},{"key":"3227_CR11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.pharmthera.2019.06.004","volume":"202","author":"T Asatsuma-Okumura","year":"2019","unstructured":"Asatsuma-Okumura, T., Ito, T., and Handa, H. (2019). Molecular mechanisms of cereblon-based drugs. Pharmacol Ther 202, 132\u2013139.","journal-title":"Pharmacol Ther"},{"key":"3227_CR12","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.3324\/haematol.2022.281628","volume":"108","author":"N Asherie","year":"2023","unstructured":"Asherie, N., Kfir-Erenfeld, S., Avni, B., Assayag, M., Dubnikov, T., Zalcman, N., Lebel, E., Zimran, E., Shaulov, A., Pick, M., et al. (2023). Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed\/refractory multiple myeloma: Results from a phase I clinical trial. Haematologica 108, 1827\u20131839.","journal-title":"Haematologica"},{"key":"3227_CR13","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/leu.2013.310","volume":"28","author":"D Atanackovic","year":"2014","unstructured":"Atanackovic, D., Luetkens, T., and Kr\u00f6ger, N. (2014). Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia 28, 993\u20131000.","journal-title":"Leukemia"},{"key":"3227_CR14","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","volume":"29","author":"NJ Bahlis","year":"2023","unstructured":"Bahlis, N.J., Costello, C.L., Raje, N.S., Levy, M.Y., Dholaria, B., Solh, M., Tomasson, M. H., Damore, M.A., Jiang, S., Basu, C., et al. (2023). Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med 29, 2570\u20132576.","journal-title":"Nat Med"},{"key":"3227_CR15","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.3324\/haematol.2019.217943","volume":"105","author":"S Barrio","year":"2020","unstructured":"Barrio, S., Munawar, U., Zhu, Y.X., Giesen, N., Shi, C.X., Vi\u00e1, M.D., Sanchez, R., Bruins, L., Demler, T., M\u00fcller, N., et al. (2020). IKZF1\/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma. Haematologica 105, e237\u2013e241.","journal-title":"Haematologica"},{"key":"3227_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41408-022-00645-1","volume":"12","author":"AH Bazarbachi","year":"2022","unstructured":"Bazarbachi, A.H., Al Hamed, R., Malard, F., Bazarbachi, A., Harousseau, J.L., and Mohty, M. (2022). Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update. Blood Cancer J 12, 47.","journal-title":"Blood Cancer J"},{"key":"3227_CR17","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.ccell.2022.06.001","volume":"40","author":"JA Belk","year":"2022","unstructured":"Belk, J.A., Yao, W., Ly, N., Freitas, K.A., Chen, Y.T., Shi, Q., Valencia, A.M., Shifrut, E., Kale, N., Yost, K.E., et al. (2022). Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence. Cancer Cell 40, 768\u2013786.e7.","journal-title":"Cancer Cell"},{"key":"3227_CR18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1182\/blood-2023-174177","volume":"142","author":"SA Bird","year":"2023","unstructured":"Bird, S.A., and Pawlyn, C. (2023). IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact. Blood 142, 131.","journal-title":"Blood"},{"key":"3227_CR19","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1182\/blood.2019001843","volume":"134","author":"MR Bishop","year":"2019","unstructured":"Bishop, M.R. (2019). The case for CAR T-cell therapy in follicular lymphomas. Blood 134, 577\u2013578.","journal-title":"Blood"},{"key":"3227_CR20","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","volume":"34","author":"CC Bjorklund","year":"2020","unstructured":"Bjorklund, C.C., Kang, J., Amatangelo, M., Polonskaia, A., Katz, M., Chiu, H., Couto, S., Wang, M., Ren, Y., Ortiz, M., et al. (2020). Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia 34, 1197\u20131201.","journal-title":"Leukemia"},{"key":"3227_CR21","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1016\/j.ymthe.2018.06.012","volume":"26","author":"J Bluhm","year":"2018","unstructured":"Bluhm, J., Kieback, E., Marino, S.F., Oden, F., Westermann, J., Chmielewski, M., Abken, H., Uckert, W., H\u00f6pken, U.E., and Rehm, A. (2018). CAR T cells with enhanced sensitivity to B cell maturation antigen for the targeting of B cell non-Hodgkin\u2019s lymphoma and multiple myeloma. Mol Ther 26, 1906\u20131920.","journal-title":"Mol Ther"},{"key":"3227_CR22","doi-asserted-by":"publisher","first-page":"7040","DOI":"10.1038\/s41467-022-33944-z","volume":"13","author":"R Boiarsky","year":"2022","unstructured":"Boiarsky, R., Haradhvala, N.J., Alberge, J.B., Sklavenitis-Pistofidis, R., Mouhieddine, T. H., Zavidij, O., Shih, M.C., Firer, D., Miller, M., El-Khoury, H., et al. (2022). Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis. Nat Commun 13, 7040.","journal-title":"Nat Commun"},{"key":"3227_CR23","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.ccell.2024.05.026","volume":"42","author":"A Bolomsky","year":"2024","unstructured":"Bolomsky, A., Ceribelli, M., Scheich, S., Rinaldi, K., Huang, D.W., Chakraborty, P., Pham, L., Wright, G.W., Hsiao, T., Morris, V., et al. (2024). IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. Cancer Cell 42, 1185\u20131201. e14.","journal-title":"Cancer Cell"},{"key":"3227_CR24","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.1007\/s10238-023-01205-y","volume":"23","author":"E Borsi","year":"2023","unstructured":"Borsi, E., Mazzocchetti, G., Dico, A.F., Vigliotta, I., Martello, M., Poletti, A., Solli, V., Armuzzi, S., Taurisano, B., Kanapari, A., et al. (2023). High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients. Clin Exp Med 23, 5227\u20135239.","journal-title":"Clin Exp Med"},{"key":"3227_CR25","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.3390\/cells11213365","volume":"11","author":"K Brennan","year":"2022","unstructured":"Brennan, K., Iversen, K.F., Blanco-Fern\u00e1ndez, A., Lund, T., Plesner, T., and Mc Gee, M.M. (2022). Extracellular vesicles isolated from plasma of multiple myeloma patients treated with daratumumab express CD38, PD-L1, and the complement inhibitory proteins CD55 and CD59. Cells 11, 3365.","journal-title":"Cells"},{"key":"3227_CR26","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1158\/1535-7163.MCT-21-0552","volume":"21","author":"JM Buonato","year":"2022","unstructured":"Buonato, J.M., Edwards, J.P., Zaritskaya, L., Witter, A.R., Gupta, A., LaFleur, D.W., Tice, D.A., Richman, L.K., and Hilbert, D.M. (2022). Preclinical efficacy of BCMA-directed CAR T cells incorporating a novel D domain antigen recognition domain. Mol Cancer Ther 21, 1171\u20131183.","journal-title":"Mol Cancer Ther"},{"key":"3227_CR27","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3390\/cancers10060198","volume":"10","author":"CM Calton","year":"2018","unstructured":"Calton, C.M., Kelly, K.R., Anwer, F., Carew, J.S., and Nawrocki, S.T. (2018). Oncolytic viruses for multiple myeloma therapy. Cancers 10, 198.","journal-title":"Cancers"},{"key":"3227_CR28","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K.M., and Kochenderfer, J.N. (2023). Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol 20, 359\u2013371.","journal-title":"Nat Rev Clin Oncol"},{"key":"3227_CR29","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41586-022-05126-w","volume":"609","author":"J Carnevale","year":"2022","unstructured":"Carnevale, J., Shifrut, E., Kale, N., Nyberg, W.A., Blaeschke, F., Chen, Y.Y., Li, Z., Bapat, S.P., Diolaiti, M.E., O\u2019Leary, P., et al. (2022). RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature 609, 174\u2013182.","journal-title":"Nature"},{"key":"3227_CR30","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1084\/jem.20182375","volume":"216","author":"M Cazaux","year":"2019","unstructured":"Cazaux, M., Grandjean, C.L., Lema\u00eetre, F., Garcia, Z., Beck, R.J., Milo, I., Postat, J., Beltman, J.B., Cheadle, E.J., and Bousso, P. (2019). Single-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity. J Exp Med 216, 1038\u20131049.","journal-title":"J Exp Med"},{"key":"3227_CR31","doi-asserted-by":"publisher","first-page":"4763","DOI":"10.1182\/blood-2021-150783","volume":"138","author":"R Chakraborty","year":"2021","unstructured":"Chakraborty, R., Yan, Y., and Royal, M. (2021). A phase 1, open-label, dose-escalation study of the safety and efficacy of anti-CD38 antibody drug conjugate (STI-6129) in patients with relapsed or refractory multiple myeloma. Blood 138, 4763.","journal-title":"Blood"},{"key":"3227_CR32","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1182\/blood.2019000722","volume":"134","author":"A Chari","year":"2019","unstructured":"Chari, A., Martinez-Lopez, J., Mateos, M.V., Blad\u00e9, J., Benboubker, L., Oriol, A., Arnulf, B., Rodriguez-Otero, P., Pineiro, L., Jakubowiak, A., et al. (2019). Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood 134, 421\u2013431.","journal-title":"Blood"},{"key":"3227_CR33","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari, A., Minnema, M.C., Berdeja, J.G., Oriol, A., van de Donk, N.W.C.J., Rodr\u00edguez-Otero, P., Askari, E., Mateos, M.V., Costa, L.J., Caers, J., et al. (2022). Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med 387, 2232\u20132244.","journal-title":"N Engl J Med"},{"key":"3227_CR34","doi-asserted-by":"publisher","first-page":"4666","DOI":"10.3390\/cancers13184666","volume":"13","author":"G Charli\u0144ski","year":"2021","unstructured":"Charli\u0144ski, G., Vesole, D.H., and Jurczyszyn, A. (2021). Rapid progress in the use of immunomodulatory drugs and cereblon E3 ligase modulators in the treatment of multiple myeloma. Cancers 13, 4666.","journal-title":"Cancers"},{"key":"3227_CR35","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41408-022-00716-3","volume":"12","author":"H Chen","year":"2022","unstructured":"Chen, H., Yu, T., Lin, L., Xing, L., Cho, S.F., Wen, K., Aardalen, K., Oka, A., Lam, J., Daley, M., et al. (2022a). \u03b3-Secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation. Blood Cancer J 12, 118.","journal-title":"Blood Cancer J"},{"key":"3227_CR36","doi-asserted-by":"publisher","first-page":"1038329","DOI":"10.3389\/fonc.2022.1038329","volume":"12","author":"LY Chen","year":"2022","unstructured":"Chen, L.Y., and Gooding, S. (2022). Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma. Front Oncol 12, 1038329.","journal-title":"Front Oncol"},{"key":"3227_CR37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40364-023-00502-8","volume":"11","author":"M Chen","year":"2023","unstructured":"Chen, M., Jiang, J., and Hou, J. (2023). Single-cell technologies in multiple myeloma: new insights into disease pathogenesis and translational implications. Biomark Res 11, 55.","journal-title":"Biomark Res"},{"key":"3227_CR38","doi-asserted-by":"publisher","first-page":"2411082","DOI":"10.1002\/advs.202411082","volume":"12","author":"R Chen","year":"2025","unstructured":"Chen, R., Li, Z., Fang, Z., Li, Z., Yang, D., Li, Y., Liu, S., Liu, Z., Liu, R., and Liu, H. (2025). Chemotherapy-mediated induction of PD-L1 via SEI1 facilitates myeloma immune evasion. Adv Sci 12, 2411082.","journal-title":"Adv Sci"},{"key":"3227_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12943-021-01466-9","volume":"21","author":"Y Chen","year":"2022","unstructured":"Chen, Y., Li, L., Lan, J., Cui, Y., Rao, X., Zhao, J., Xing, T., Ju, G., Song, G., Lou, J., et al. (2022b). CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma. Mol Cancer 21, 11.","journal-title":"Mol Cancer"},{"key":"3227_CR40","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/leu.2017.329","volume":"32","author":"CS Chim","year":"2018","unstructured":"Chim, C.S., Kumar, S.K., Orlowski, R.Z., Cook, G., Richardson, P.G., Gertz, M.A., Giralt, S., Mateos, M.V., Leleu, X., and Anderson, K.C. (2018). Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia 32, 252\u2013262.","journal-title":"Leukemia"},{"key":"3227_CR41","doi-asserted-by":"publisher","first-page":"108007","DOI":"10.1016\/j.pharmthera.2021.108007","volume":"232","author":"T Choi","year":"2022","unstructured":"Choi, T., and Kang, Y. (2022). Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma. Pharmacol Ther 232, 108007.","journal-title":"Pharmacol Ther"},{"key":"3227_CR42","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1158\/0008-5472.CAN-19-0343","volume":"79","author":"PSY Chong","year":"2019","unstructured":"Chong, P.S.Y., Zhou, J., Lim, J.S.L., Hee, Y.T., Chooi, J.Y., Chung, T.H., Tan, Z.T., Zeng, Q., Waller, D.D., Sebag, M., et al. (2019). IL6 promotes a STAT3-PRL3 feedforward loop via SHP2 repression in multiple myeloma. Cancer Res 79, 4679\u20134688.","journal-title":"Cancer Res"},{"key":"3227_CR43","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1182\/blood.2021015184","volume":"140","author":"F Cichocki","year":"2022","unstructured":"Cichocki, F., Goodridge, J.P., Bjordahl, R., Mahmood, S., Davis, Z.B., Gaidarova, S., Abujarour, R., Groff, B., Witty, A., Wang, H., et al. (2022). Dual antigen-targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia. Blood 140, 2451\u20132462.","journal-title":"Blood"},{"key":"3227_CR44","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41591-021-01232-w","volume":"27","author":"YC Cohen","year":"2021","unstructured":"Cohen, Y.C., Zada, M., Wang, S.Y., Bornstein, C., David, E., Moshe, A., Li, B., Shlomi-Loubaton, S., Gatt, M.E., Gur, C., et al. (2021). Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat Med 27, 491\u2013503.","journal-title":"Nat Med"},{"key":"3227_CR45","doi-asserted-by":"publisher","first-page":"7814","DOI":"10.3390\/ijms21217814","volume":"21","author":"C Coppola","year":"2020","unstructured":"Coppola, C., Hopkins, B., Huhn, S., Du, Z., Huang, Z., and Kelly, W.J. (2020). Investigation of the impact from IL-2, IL-7, and IL-15 on the growth and signaling of activated CD4+ T cells. Int J Mol Sci 21, 7814.","journal-title":"Int J Mol Sci"},{"key":"3227_CR46","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/ajh.27225","volume":"99","author":"BA Costa","year":"2024","unstructured":"Costa, B.A., Ortiz, R.J., Lesokhin, A.M., and Richter, J. (2024). Soluble B-cell maturation antigen in multiple myeloma. Am J Hematol 99, 727\u2013738.","journal-title":"Am J Hematol"},{"key":"3227_CR47","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","volume":"24","author":"AJ Cowan","year":"2023","unstructured":"Cowan, A.J., Pont, M.J., Sather, B.D., Turtle, C.J., Till, B.G., Libby 3rd, E.N., Coffey, D. G., Tuazon, S.A., Wood, B., Gooley, T., et al. (2023). \u03b3-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. Lancet Oncol 24, 811\u2013822.","journal-title":"Lancet Oncol"},{"key":"3227_CR48","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/d41573-022-00043-z","volume":"21","author":"S Crunkhorn","year":"2022","unstructured":"Crunkhorn, S. (2022). Antibody-based therapy for multiple myeloma. Nat Rev Drug Discov 21, 260.","journal-title":"Nat Rev Drug Discov"},{"key":"3227_CR49","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ccell.2023.05.007","volume":"41","author":"M Dang","year":"2023","unstructured":"Dang, M., Han, G., Lee, H.C., Patel, K.K., Becnel, M.R., Wang, R., Thomas, S.K., Hao, D., Chu, Y., Weber, D.M., et al. (2023). Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease. Cancer Cell 41, 1032\u20131047.e4.","journal-title":"Cancer Cell"},{"key":"3227_CR50","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ccell.2021.06.012","volume":"39","author":"GM Delgoffe","year":"2021","unstructured":"Delgoffe, G.M., Xu, C., Mackall, C.L., Green, M.R., Gottschalk, S., Speiser, D.E., Zehn, D., and Beavis, P.A. (2021). The role of exhaustion in CAR T cell therapy. Cancer Cell 39, 885\u2013888.","journal-title":"Cancer Cell"},{"key":"3227_CR51","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1182\/blood.2025029773","volume":"146","author":"B Dhakal","year":"2025","unstructured":"Dhakal, B., Akhtar, O.S., Fandrei, D., Jensen, A., Banerjee, R., Pan, D., Richard, S., Friend, R., Rees, M., Costello, P., et al. (2025). Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy. Blood 146, 2063\u20132072.","journal-title":"Blood"},{"key":"3227_CR52","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","volume":"21","author":"A Dimitri","year":"2022","unstructured":"Dimitri, A., Herbst, F., and Fraietta, J.A. (2022). Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Mol Cancer 21, 78.","journal-title":"Mol Cancer"},{"key":"3227_CR53","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-018-0583-7","volume":"11","author":"M Dimopoulos","year":"2018","unstructured":"Dimopoulos, M., Wang, M., Maisnar, V., Minarik, J., Bensinger, W., Mateos, M.V., Obreja, M., Blaedel, J., and Moreau, P. (2018a). Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. J Hematol Oncol 11, 49.","journal-title":"J Hematol Oncol"},{"key":"3227_CR54","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2403407","volume":"391","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos, M.A., Beksac, M., Pour, L., Delimpasi, S., Vorobyev, V., Quach, H., Spicka, I., Radocha, J., Robak, P., Kim, K., et al. (2024). Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med 391, 408\u2013421.","journal-title":"N Engl J Med"},{"key":"3227_CR55","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","volume":"379","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos, M.A., Dytfeld, D., Grosicki, S., Moreau, P., Takezako, N., Hori, M., Leleu, X., LeBlanc, R., Suzuki, K., Raab, M.S., et al. (2018b). Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med 379, 1811\u20131822.","journal-title":"N Engl J Med"},{"key":"3227_CR56","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1200\/JCO.21.02815","volume":"41","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos, M.A., Dytfeld, D., Grosicki, S., Moreau, P., Takezako, N., Hori, M., Leleu, X., LeBlanc, R., Suzuki, K., Raab, M.S., et al. (2023). Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial. J Clin Oncol 41, 568\u2013578.","journal-title":"J Clin Oncol"},{"key":"3227_CR57","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/bjh.14549","volume":"177","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos, M.A., Stewart, A.K., Masszi, T., \u0160pi\u010dka, I., Oriol, A., H\u00e1jek, R., Rosi\u00f1ol, L., Siegel, D., Mihaylov, G.G., Goranova-Marinova, V., et al. (2017a). Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. Br J Haematol 177, 404\u2013413.","journal-title":"Br J Haematol"},{"key":"3227_CR58","doi-asserted-by":"publisher","first-page":"e554","DOI":"10.1038\/bcj.2017.31","volume":"7","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos, M.A., Stewart, A.K., Masszi, T., \u0160pi\u010dka, I., Oriol, A., H\u00e1jek, R., Rosi\u00f1ol, L., Siegel, D., Mihaylov, G.G., Goranova-Marinova, V., et al. (2017b). Carfilzomiblenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. Blood Cancer J 7, e554.","journal-title":"Blood Cancer J"},{"key":"3227_CR59","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1016\/j.apsb.2023.06.016","volume":"13","author":"Y Dong","year":"2023","unstructured":"Dong, Y., Chen, Y., Ma, G., and Cao, H. (2023). The role of E3 ubiquitin ligases in bone homeostasis and related diseases. Acta Pharm Sin B 13, 3963\u20133987.","journal-title":"Acta Pharm Sin B"},{"key":"3227_CR60","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet, C., Reichert, J.M., Senter, P.D., Lambert, J.M., and Beck, A. (2023). Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov 22, 641\u2013661.","journal-title":"Nat Rev Drug Discov"},{"key":"3227_CR61","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BGM Durie","year":"2017","unstructured":"Durie, B.G.M., Hoering, A., Abidi, M.H., Rajkumar, S.V., Epstein, J., Kahanic, S.P., Thakuri, M., Reu, F., Reynolds, C.M., Sexton, R., et al. (2017). Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389, 519\u2013527.","journal-title":"Lancet"},{"key":"3227_CR62","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41571-021-00593-y","volume":"19","author":"AK Dutta","year":"2022","unstructured":"Dutta, A.K., Alberge, J.B., Sklavenitis-Pistofidis, R., Lightbody, E.D., Getz, G., and Ghobrial, I.M. (2022). Single-cell profiling of tumour evolution in multiple myeloma\u2014opportunities for precision medicine. Nat Rev Clin Oncol 19, 223\u2013236.","journal-title":"Nat Rev Clin Oncol"},{"key":"3227_CR63","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3324\/haematol.2023.283073","volume":"109","author":"T Facon","year":"2024","unstructured":"Facon, T., Moreau, P., Baker, R., Min, C.K., Leleu, X., Mohty, M., Karlin, L., Armstrong, N.M., Tekle, C., Schwab, S., et al. (2024). Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis. Haematologica 109, 604\u2013616.","journal-title":"Haematologica"},{"key":"3227_CR64","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood.2020008787","volume":"137","author":"T Facon","year":"2021","unstructured":"Facon, T., Venner, C.P., Bahlis, N.J., Offner, F., White, D.J., Karlin, L., Benboubker, L., Rigaudeau, S., Rodon, P., Voog, E., et al. (2021). Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood 137, 3616\u20133628.","journal-title":"Blood"},{"key":"3227_CR65","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","volume":"1","author":"C Fern\u00e1ndez de Larrea","year":"2020","unstructured":"Fern\u00e1ndez de Larrea, C., Staehr, M., Lopez, A.V., Ng, K.Y., Chen, Y., Godfrey, W.D., Purdon, T.J., Ponomarev, V., Wendel, H.G., Brentjens, R.J., et al. (2020). Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma. Blood Cancer Discov 1, 146\u2013154.","journal-title":"Blood Cancer Discov"},{"key":"3227_CR66","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1158\/1535-7163.MCT-20-0287","volume":"20","author":"V Figueroa-Vazquez","year":"2021","unstructured":"Figueroa-Vazquez, V., Ko, J., Breunig, C., Baumann, A., Giesen, N., P\u00e1lfi, A., M\u00fcller, C., Lutz, C., Hechler, T., Kulke, M., et al. (2021). HDP-101, an anti-BCMA antibody-drug conjugate, safely delivers amanitin to induce cell death in proliferating and resting multiple myeloma cells. Mol Cancer Ther 20, 367\u2013378.","journal-title":"Mol Cancer Ther"},{"key":"3227_CR67","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1158\/2643-3230.BCD-23-0176","volume":"4","author":"R Firestone","year":"2023","unstructured":"Firestone, R., Lesokhin, A.M., and Usmani, S.Z. (2023). An embarrassment of riches: three FDA-approved bispecific antibodies for relapsed refractory multiple myeloma. Blood Cancer Discov 4, 433\u2013436.","journal-title":"Blood Cancer Discov"},{"key":"3227_CR68","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature13527","volume":"512","author":"ES Fischer","year":"2014","unstructured":"Fischer, E.S., B\u00f6hm, K., Lydeard, J.R., Yang, H., Stadler, M.B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G.M., et al. (2014). Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 512, 49\u201353.","journal-title":"Nature"},{"key":"3227_CR69","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1182\/blood.2024024965","volume":"145","author":"CL Freeman","year":"2025","unstructured":"Freeman, C.L., Noble, J., Menges, M., Villanueva, R., Nakashima, J.Y., Figura, N.B., Tonseth, R.P., Werner Idiaquez, D., Skelson, L., Smith, E., et al. (2025). Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes. Blood 145, 1645\u20131657.","journal-title":"Blood"},{"key":"3227_CR70","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1182\/bloodadvances.2022007210","volume":"7","author":"MJ Frigault","year":"2023","unstructured":"Frigault, M.J., Bishop, M.R., Rosenblatt, J., O\u2019Donnell, E.K., Raje, N., Cook, D., Yee, A. J., Logan, E., Avigan, D.E., Jakubowiak, A., et al. (2023). Phase 1 study of CARTddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood Adv 7, 768\u2013777.","journal-title":"Blood Adv"},{"key":"3227_CR71","doi-asserted-by":"publisher","first-page":"100994","DOI":"10.1016\/j.blre.2022.100994","volume":"57","author":"O Fuchs","year":"2023","unstructured":"Fuchs, O. (2023). Targeting cereblon in hematologic malignancies. Blood Rev 57, 100994.","journal-title":"Blood Rev"},{"key":"3227_CR72","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi, U.H., Cornell, R.F., Lakshman, A., Gahvari, Z.J., McGehee, E., Jagosky, M.H., Gupta, R., Varnado, W., Fiala, M.A., Chhabra, S., et al. (2019). Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia 33, 2266\u20132275.","journal-title":"Leukemia"},{"key":"3227_CR73","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1182\/blood.2020007081","volume":"137","author":"S Gooding","year":"2021","unstructured":"Gooding, S., Ansari-Pour, N., Towfic, F., Ortiz Est\u00e9vez, M., Chamberlain, P.P., Tsai, K. T., Flynt, E., Hirst, M., Rozelle, D., Dhiman, P., et al. (2021). Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. Blood 137, 232\u2013237.","journal-title":"Blood"},{"key":"3227_CR74","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/nri3582","volume":"14","author":"M Guilliams","year":"2014","unstructured":"Guilliams, M., Bruhns, P., Saeys, Y., Hammad, H., and Lambrecht, B.N. (2014). The function of Fc\u03b3 receptors in dendritic cells and macrophages. Nat Rev Immunol 14, 94\u2013108.","journal-title":"Nat Rev Immunol"},{"key":"3227_CR75","doi-asserted-by":"publisher","first-page":"103941","DOI":"10.1016\/j.ebiom.2022.103941","volume":"77","author":"D Gumber","year":"2022","unstructured":"Gumber, D., and Wang, L.D. (2022). Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion. eBioMedicine 77, 103941.","journal-title":"eBioMedicine"},{"key":"3227_CR76","doi-asserted-by":"publisher","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","volume":"63","author":"JD Hansen","year":"2020","unstructured":"Hansen, J.D., Correa, M., Nagy, M.A., Alexander, M., Plantevin, V., Grant, V., Whitefield, B., Huang, D., Kercher, T., Harris, R., et al. (2020). Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma. J Med Chem 63, 6648\u20136676.","journal-title":"J Med Chem"},{"key":"3227_CR77","doi-asserted-by":"publisher","first-page":"e757","DOI":"10.1002\/ctm2.757","volume":"12","author":"H He","year":"2022","unstructured":"He, H., Li, Z., Lu, J., Qiang, W., Jiang, S., Xu, Y., Fu, W., Zhai, X., Zhou, L., Qian, M., et al. (2022). Single-cell RNA-seq reveals clonal diversity and prognostic genes of relapsed multiple myeloma. Clin Transl Med 12, e757.","journal-title":"Clin Transl Med"},{"key":"3227_CR78","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41591-023-02734-5","volume":"30","author":"MC Heinrich","year":"2024","unstructured":"Heinrich, M.C., Jones, R.L., George, S., Gelderblom, H., Sch\u00f6ffski, P., von Mehren, M., Zalcberg, J.R., Kang, Y.K., Razak, A.A., Trent, J., et al. (2024). Ripretinib versus sunitinib in gastrointestinal stromal tumor: CtDNA biomarker analysis of the phase 3 INTRIGUE trial. Nat Med 30, 498\u2013506.","journal-title":"Nat Med"},{"key":"3227_CR79","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nrc2189","volume":"7","author":"T Hideshima","year":"2007","unstructured":"Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P.G., and Anderson, K.C. (2007). Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7, 585\u2013598.","journal-title":"Nat Rev Cancer"},{"key":"3227_CR80","doi-asserted-by":"publisher","first-page":"104663","DOI":"10.1016\/j.ebiom.2023.104663","volume":"93","author":"IH Hiemstra","year":"2023","unstructured":"Hiemstra, I.H., Santegoets, K.C.M., Janmaat, M.L., De Goeij, B.E.C.G., Ten Hagen, W., van Dooremalen, S., Boross, P., van den Brakel, J., Bosgra, S., Andringa, G., et al. (2023). Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity. eBioMedicine 93, 104663.","journal-title":"eBioMedicine"},{"key":"3227_CR81","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.cell.2023.03.007","volume":"186","author":"D Hirschhorn","year":"2023","unstructured":"Hirschhorn, D., Budhu, S., Kraehenbuehl, L., Gigoux, M., Schr\u00f6der, D., Chow, A., Ricca, J.M., Gasmi, B., De Henau, O., Mangarin, L.M.B., et al. (2023). T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants. Cell 186, 1432\u20131447.e17.","journal-title":"Cell"},{"key":"3227_CR82","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1200\/JCO.23.00512","volume":"41","author":"SA Holstein","year":"2023","unstructured":"Holstein, S.A., Grant, S.J., and Wildes, T.M. (2023). Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future. J Clin Oncol 41, 4416\u20134429.","journal-title":"J Clin Oncol"},{"key":"3227_CR83","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","volume":"77","author":"SA Holstein","year":"2017","unstructured":"Holstein, S.A., and McCarthy, P.L. (2017). Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience. Drugs 77, 505\u2013520.","journal-title":"Drugs"},{"key":"3227_CR84","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/2040620718775629","volume":"9","author":"SA Holstein","year":"2018","unstructured":"Holstein, S.A., Suman, V.J., and McCarthy, P.L. (2018). Update on the role of lenalidomide in patients with multiple myeloma. Ther Adv Hematol 9, 175\u2013190.","journal-title":"Ther Adv Hematol"},{"key":"3227_CR85","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40164-023-00436-9","volume":"12","author":"J Hou","year":"2023","unstructured":"Hou, J., Li, Y., and Lin, Q. (2023). Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting. Exp Hematol Oncol 12, 74.","journal-title":"Exp Hematol Oncol"},{"key":"3227_CR86","doi-asserted-by":"publisher","first-page":"6020","DOI":"10.1158\/1538-7445.AM2022-6020","volume":"82","author":"W Huang","year":"2022","unstructured":"Huang, W., Luo, J., Li, Y., Fei, D., Qin, X., and Li, R. (2022). Abstract 6020: preclinical activity of LM-305 targeting G-protein-coupled receptor class 5 member D (GPRC5D) antibody drug conjugate for the treatment of multiple myeloma. Cancer Res 82, 6020.","journal-title":"Cancer Res"},{"key":"3227_CR87","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2405090","volume":"391","author":"V Hungria","year":"2024","unstructured":"Hungria, V., Robak, P., Hus, M., Zherebtsova, V., Ward, C., Ho, P.J., Ribas de Almeida, A.C., Hajek, R., Kim, K., Grosicki, S., et al. (2024). Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 391, 393\u2013407.","journal-title":"N Engl J Med"},{"key":"3227_CR88","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nm.4474","volume":"24","author":"ML Hyer","year":"2018","unstructured":"Hyer, M.L., Milhollen, M.A., Ciavarri, J., Fleming, P., Traore, T., Sappal, D., Huck, J., Shi, J., Gavin, J., Brownell, J., et al. (2018). A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment. Nat Med 24, 186\u2013193.","journal-title":"Nat Med"},{"key":"3227_CR89","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1182\/bloodadvances.2022008966","volume":"7","author":"DN Iyer","year":"2023","unstructured":"Iyer, D.N., Schimmer, A.D., and Chang, H. (2023). Applying CRISPR-Cas9 screens to dissect hematological malignancies. Blood Adv 7, 2252\u20132270.","journal-title":"Blood Adv"},{"key":"3227_CR90","doi-asserted-by":"publisher","first-page":"7581","DOI":"10.1182\/bloodadvances.2023011428","volume":"7","author":"Y Jian","year":"2023","unstructured":"Jian, Y., Chang, L., Shi, M.X., Sun, Y., Chu, X.X., Xue, H., Huang, W.R., Shen, X.L., Ma, J., Jia, G.R., et al. (2023). Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment. Blood Adv 7, 7581\u20137584.","journal-title":"Blood Adv"},{"key":"3227_CR91","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/s41375-020-01085-1","volume":"35","author":"Z Jiang","year":"2021","unstructured":"Jiang, Z., Liao, R., Lv, J., Li, S., Zheng, D., Qin, L., Wu, D., Chen, S., Long, Y., Wu, Q., et al. (2021). IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells. Leukemia 35, 1380\u20131391.","journal-title":"Leukemia"},{"key":"3227_CR92","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41586-021-03741-7","volume":"595","author":"H Jin","year":"2021","unstructured":"Jin, H., Shi, Y., Lv, Y., Yuan, S., Ramirez, C.F.A., Lieftink, C., Wang, L., Wang, S., Wang, C., Dias, M.H., et al. (2021). EGFR activation limits the response of liver cancer to lenvatinib. Nature 595, 730\u2013734.","journal-title":"Nature"},{"key":"3227_CR93","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1038\/s41375-021-01373-4","volume":"35","author":"JR Jones","year":"2021","unstructured":"Jones, J.R., Barber, A., Le Bihan, Y.V., Weinhold, N., Ashby, C., Walker, B.A., Wardell, C.P., Wang, H., Kaiser, M.F., Jackson, G.H., et al. (2021). Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs. Leukemia 35, 3017\u20133020.","journal-title":"Leukemia"},{"key":"3227_CR94","doi-asserted-by":"publisher","first-page":"e44288","DOI":"10.7554\/eLife.44288","volume":"8","author":"S Kabir","year":"2019","unstructured":"Kabir, S., Cidado, J., Andersen, C., Dick, C., Lin, P.C., Mitros, T., Ma, H., Baik, S.H., Belmonte, M.A., Drew, L., et al. (2019). The CUL5 ubiquitin ligase complex mediates resistance to CDK9 and MCL1 inhibitors in lung cancer cells. eLife 8, e44288.","journal-title":"eLife"},{"key":"3227_CR95","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1182\/blood.2021012448","volume":"139","author":"S Kassem","year":"2022","unstructured":"Kassem, S., Diallo, B.K., El-Murr, N., Carri\u00e9, N., Tang, A., Fournier, A., Bonnevaux, H., Nicolazzi, C., Cuisinier, M., Arnould, I., et al. (2022). SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma. Blood 139, 1160\u20131176.","journal-title":"Blood"},{"key":"3227_CR96","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1016\/S2152-2650(22)00341-X","volume":"22","author":"J Kaufman","year":"2022","unstructured":"Kaufman, J., Atrash, S., Benson, D., Holstein, S., Nadeem, O., Biran, N., Suryanarayan, K., Liu, Y., Robinson, L.S., Correa, K., et al. (2022). P-011: A randomized phase 2 study of modakafusp alfa (TAK-573) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) with a pilot diversity, equity, and inclusion (DEI) strategy. Clin Lymphoma Myeloma Leuk 22, S42.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3227_CR97","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-022-01296-2","volume":"15","author":"D Kegyes","year":"2022","unstructured":"Kegyes, D., Constantinescu, C., Vrancken, L., Rasche, L., Gregoire, C., Tigu, B., Gulei, D., Dima, D., Tanase, A., Einsele, H., et al. (2022). Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient? J Hematol Oncol 15, 78.","journal-title":"J Hematol Oncol"},{"key":"3227_CR98","doi-asserted-by":"publisher","first-page":"e794","DOI":"10.1016\/S2352-3026(21)00208-8","volume":"8","author":"KR Kelly","year":"2021","unstructured":"Kelly, K.R., Ailawadhi, S., Siegel, D.S., Heffner, L.T., Somlo, G., Jagannath, S., Zimmerman, T.M., Munshi, N.C., Madan, S., Chanan-Khan, A., et al. (2021). Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1\/2a study. Lancet Haematol 8, e794\u2013e807.","journal-title":"Lancet Haematol"},{"key":"3227_CR99","doi-asserted-by":"publisher","first-page":"e95103","DOI":"10.1172\/jci.insight.95103","volume":"2","author":"CA Klebanoff","year":"2017","unstructured":"Klebanoff, C.A., Crompton, J.G., Leonardi, A.J., Yamamoto, T.N., Chandran, S.S., Eil, R.L., Sukumar, M., Vodnala, S.K., Hu, J., Ji, Y., et al. (2017). Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. JCI Insight 2, e95103.","journal-title":"JCI Insight"},{"key":"3227_CR100","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/j.cell.2022.03.041","volume":"185","author":"L Labanieh","year":"2022","unstructured":"Labanieh, L., Majzner, R.G., Klysz, D., Sotillo, E., Fisher, C.J., Vilches-Moure, J.G., Pacheco, K.Z.B., Malipatlolla, M., Xu, P., Hui, J.H., et al. (2022). Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. Cell 185, 1745\u20131763.e22.","journal-title":"Cell"},{"key":"3227_CR101","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1158\/2643-3230.BCD-21-0028","volume":"2","author":"G Lancman","year":"2021","unstructured":"Lancman, G., Sastow, D.L., Cho, H.J., Jagannath, S., Madduri, D., Parekh, S.S., Richard, S., Richter, J., Sanchez, L., and Chari, A. (2021). Bispecific antibodies in multiple myeloma: present and future. Blood Cancer Discov 2, 423\u2013433.","journal-title":"Blood Cancer Discov"},{"key":"3227_CR102","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1001\/jamaoncol.2021.0611","volume":"7","author":"O Landgren","year":"2021","unstructured":"Landgren, O., Hultcrantz, M., Diamond, B., Lesokhin, A.M., Mailankody, S., Hassoun, H., Tan, C., Shah, U.A., Lu, S.X., Salcedo, M., et al. (2021). Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma. JAMA Oncol 7, 862.","journal-title":"JAMA Oncol"},{"key":"3227_CR103","doi-asserted-by":"publisher","first-page":"7509","DOI":"10.1038\/s41467-023-43416-7","volume":"14","author":"RC Larson","year":"2023","unstructured":"Larson, R.C., Kann, M.C., Graham, C., Mount, C.W., Castano, A.P., Lee, W.H., Bouffard, A.A., Takei, H.N., Almazan, A.J., Scarf\u00f3, I., et al. (2023). Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma. Nat Commun 14, 7509.","journal-title":"Nat Commun"},{"key":"3227_CR104","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson, R.C., and Maus, M.V. (2021). Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer 21, 145\u2013161.","journal-title":"Nat Rev Cancer"},{"key":"3227_CR105","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","volume":"6","author":"SA Laurent","year":"2015","unstructured":"Laurent, S.A., Hoffmann, F.S., Kuhn, P.H., Cheng, Q., Chu, Y., Schmidt-Supprian, M., Hauck, S.M., Schuh, E., Krumbholz, M., R\u00fcbsamen, H., et al. (2015). \u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun 6, 7333.","journal-title":"Nat Commun"},{"key":"3227_CR106","doi-asserted-by":"publisher","first-page":"e178766","DOI":"10.1172\/jci.insight.178766","volume":"10","author":"ST Le","year":"2025","unstructured":"Le, S.T., Marusina, A.I., Merleev, A.A., Kirane, A., Kruglinskaya, O., Kunitsyn, A., Kuzminykh, N.Y., Xing, X., Li, S.Y., Liakos, W., et al. (2025). SPP1hi macrophages, NKG7 T cells, CCL5hi fibroblasts, and IgM plasma cells are dominant features of necrobiosis. JCI Insight 10, e178766.","journal-title":"JCI Insight"},{"key":"3227_CR107","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3389\/fonc.2020.00636","volume":"10","author":"N Leblay","year":"2020","unstructured":"Leblay, N., Maity, R., Hasan, F., and Neri, P. (2020). Deregulation of adaptive T cell immunity in multiple myeloma: insights into mechanisms and therapeutic opportunities. Front Oncol 10, 636.","journal-title":"Front Oncol"},{"key":"3227_CR108","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41375-020-0834-9","volume":"35","author":"HC Lee","year":"2021","unstructured":"Lee, H.C., Raje, N.S., Landgren, O., Upreti, V.V., Wang, J., Avilion, A.A., Hu, X., Rasmussen, E., Ngarmchamnanrith, G., Fujii, H., et al. (2021). Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed\/refractory multiple myeloma. Leukemia 35, 255\u2013258.","journal-title":"Leukemia"},{"key":"3227_CR109","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","volume":"131","author":"L Lee","year":"2018","unstructured":"Lee, L., Draper, B., Chaplin, N., Philip, B., Chin, M., Galas-Filipowicz, D., Onuoha, S., Thomas, S., Baldan, V., Bughda, R., et al. (2018). An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma. Blood 131, 746\u2013758.","journal-title":"Blood"},{"key":"3227_CR110","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1002\/ajh.26750","volume":"98","author":"S Leong","year":"2023","unstructured":"Leong, S., Lam, H.P.J., Kirkham, Z., and Popat, R. (2023). Antibody drug conjugates for the treatment of multiple myeloma. Am J Hematol 98, S22\u2013S34.","journal-title":"Am J Hematol"},{"key":"3227_CR111","doi-asserted-by":"publisher","first-page":"10254","DOI":"10.1002\/cam4.5753","volume":"12","author":"A Lesokhin","year":"2023","unstructured":"Lesokhin, A., LeBlanc, R., Dimopoulos, M.A., Capra, M., Carlo-Stella, C., Karlin, L., Castilloux, J., Forsberg, P., Parmar, G., Tosikyan, A., et al. (2023a). Isatuximab in combination with cemiplimab in patients with relapsed\/refractory multiple myeloma: a phase 1\/2 study. Cancer Med 12, 10254\u201310266.","journal-title":"Cancer Med"},{"key":"3227_CR112","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin, A.M., Tomasson, M.H., Arnulf, B., Bahlis, N.J., Miles Prince, H., Niesvizky, R., Rodr\u03afguez-Otero, P., Martinez-Lopez, J., Koehne, G., Touzeau, C., et al. (2023b). Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 29, 2259\u20132267.","journal-title":"Nat Med"},{"key":"3227_CR113","doi-asserted-by":"publisher","first-page":"TPS7081","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7081","volume":"41","author":"W Li","year":"2023","unstructured":"Li, W., Xu, N., Xu, Z., Zhang, Y., Li, J., Zhu, H., Zheng, L., Yan, X., Du, X., Wei, H., et al. (2023a). A phase 1, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10382 (TERN-701) in patients (pts) with chronic myeloid leukemia (CML). J Clin Oncol 41, TPS7081.","journal-title":"J Clin Oncol"},{"key":"3227_CR114","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40164-023-00402-5","volume":"12","author":"W Li","year":"2023","unstructured":"Li, W., Zhang, B., Cao, W., Zhang, W., Li, T., Liu, L., Xu, L.P., Gao, F., Wang, Y., Wang, F., et al. (2023b). Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed\/refractory multiple myeloma through single-cell sequencing. Exp Hematol Oncol 12, 44.","journal-title":"Exp Hematol Oncol"},{"key":"3227_CR115","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12943-022-01648-z","volume":"21","author":"Y Liang","year":"2022","unstructured":"Liang, Y., He, H., Wang, W., Wang, H., Mo, S., Fu, R., Liu, X., Song, Q., Xia, Z., and Wang, L. (2022). Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming. Mol Cancer 21, 182.","journal-title":"Mol Cancer"},{"key":"3227_CR116","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","volume":"29","author":"Y Lin","year":"2023","unstructured":"Lin, Y., Raje, N.S., Berdeja, J.G., Siegel, D.S., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M.V., Massaro, M., et al. (2023). Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med 29, 2286\u20132294.","journal-title":"Nat Med"},{"key":"3227_CR117","doi-asserted-by":"publisher","first-page":"eabg2697","DOI":"10.1126\/sciadv.abg2697","volume":"7","author":"J Liu","year":"2021","unstructured":"Liu, J., Hideshima, T., Xing, L., Wang, S., Zhou, W., Samur, M.K., Sewastianik, T., Ogiya, D., An, G., Gao, S., et al. (2021). ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment. Sci Adv 7, eabg2697.","journal-title":"Sci Adv"},{"key":"3227_CR118","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41375-018-0205-y","volume":"33","author":"J Liu","year":"2019","unstructured":"Liu, J., Song, T., Zhou, W., Xing, L., Wang, S., Ho, M., Peng, Z., Tai, Y.T., Hideshima, T., Anderson, K.C., et al. (2019). A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity. Leukemia 33, 171\u2013180.","journal-title":"Leukemia"},{"key":"3227_CR119","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3324\/haematol.2023.283931","volume":"109","author":"L Liu","year":"2024","unstructured":"Liu, L., and Krishnan, A. (2024). Talquetamab in multiple myeloma. Haematologica 109, 718\u2013724.","journal-title":"Haematologica"},{"key":"3227_CR120","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.V., Magen, H., et al. (2015). Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373, 621\u2013631.","journal-title":"N Engl J Med"},{"key":"3227_CR121","doi-asserted-by":"publisher","first-page":"e822","DOI":"10.1016\/S2352-3026(22)00290-3","volume":"9","author":"S Lonial","year":"2022","unstructured":"Lonial, S., Popat, R., Hulin, C., Jagannath, S., Oriol, A., Richardson, P.G., Facon, T., Weisel, K., Larsen, J.T., Minnema, M.C., et al. (2022). Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1\/2 trial. Lancet Haematol 9, e822\u2013e832.","journal-title":"Lancet Haematol"},{"key":"3227_CR122","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/leu.2012.119","volume":"26","author":"A Lopez-Girona","year":"2012","unstructured":"Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A.K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012). Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26, 2326\u20132335.","journal-title":"Leukemia"},{"key":"3227_CR123","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu, G., Middleton, R.E., Sun, H., Naniong, M.V., Ott, C.J., Mitsiades, C.S., Wong, K.K., Bradner, J.E., and Kaelin Jr., W.G. (2014). The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343, 305\u2013309.","journal-title":"Science"},{"key":"3227_CR124","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","volume":"21","author":"J Lu","year":"2022","unstructured":"Lu, J., and Jiang, G. (2022). The journey of CAR-T therapy in hematological malignancies. Mol Cancer 21, 194.","journal-title":"Mol Cancer"},{"key":"3227_CR125","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn, R.C., Weber, E.W., Sotillo, E., Gennert, D., Xu, P., Good, Z., Anbunathan, H., Lattin, J., Jones, R., Tieu, V., et al. (2019). c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576, 293\u2013300.","journal-title":"Nature"},{"key":"3227_CR126","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","volume":"186","author":"L Ma","year":"2023","unstructured":"Ma, L., Hostetler, A., Morgan, D.M., Maiorino, L., Sulkaj, I., Whittaker, C.A., Neeser, A., Pires, I.S., Yousefpour, P., Gregory, J., et al. (2023). Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell 186, 3148\u20133165.e20.","journal-title":"Cell"},{"key":"3227_CR127","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1182\/blood.2023020923","volume":"142","author":"T Maeda","year":"2023","unstructured":"Maeda, T. (2023). CELMoD for ALL: an exciting prospect. Blood 142, 614\u2013615.","journal-title":"Blood"},{"key":"3227_CR128","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jcyt.2021.10.010","volume":"24","author":"HB Maganti","year":"2022","unstructured":"Maganti, H.B., Kirkham, A.M., Bailey, A.J.M., Shorr, R., Kekre, N., Pineault, N., and Allan, D.S. (2022). Use of CRISPR\/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: a systematic review and meta-analysis of preclinical studies. Cytotherapy 24, 405\u2013412.","journal-title":"Cytotherapy"},{"key":"3227_CR129","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1016\/S2352-3026(23)00366-6","volume":"11","author":"EK Mai","year":"2024","unstructured":"Mai, E.K., Goldschmidt, H., Miah, K., Bertsch, U., Besemer, B., H\u00e4nel, M., Krzykalla, J., Fenk, R., Schlenzka, J., Munder, M., et al. (2024). Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial. Lancet Haematol 11, e101\u2013e113.","journal-title":"Lancet Haematol"},{"key":"3227_CR130","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner, R.G., and Mackall, C.L. (2018). Tumor antigen escape from CAR T-cell Therapy. Cancer Discov 8, 1219\u20131226.","journal-title":"Cancer Discov"},{"key":"3227_CR131","doi-asserted-by":"publisher","first-page":"100929","DOI":"10.1016\/j.blre.2022.100929","volume":"54","author":"S Manier","year":"2022","unstructured":"Manier, S., Ingegnere, T., Escure, G., Prodhomme, C., Nudel, M., Mitra, S., and Facon, T. (2022). Current state and next-generation CAR-T cells in multiple myeloma. Blood Rev 54, 100929.","journal-title":"Blood Rev"},{"key":"3227_CR132","doi-asserted-by":"publisher","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-21-0308","volume":"27","author":"SH Manjunath","year":"2021","unstructured":"Manjunath, S.H., Cohen, A.D., Lacey, S.F., Davis, M.M., Garfall, A.L., Melenhorst, J.J., Maxwell, R., Arscott, W.T., Maity, A., Jones, J.A., et al. (2021). The safety of bridging radiation with anti-BCMA CAR T-cell therapy for multiple myeloma. Clin Cancer Res 27, 6580\u20136590.","journal-title":"Clin Cancer Res"},{"key":"3227_CR133","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1080\/14712598.2020.1802422","volume":"21","author":"A McMillan","year":"2021","unstructured":"McMillan, A., Warcel, D., and Popat, R. (2021). Antibody-drug conjugates for multiple myeloma. Expert Opin Biol Ther 21, 889\u2013901.","journal-title":"Expert Opin Biol Ther"},{"key":"3227_CR134","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","volume":"14","author":"H Mei","year":"2021","unstructured":"Mei, H., Li, C., Jiang, H., Zhao, X., Huang, Z., Jin, D., Guo, T., Kou, H., Liu, L., Tang, L., et al. (2021). A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J Hematol Oncol 14, 161.","journal-title":"J Hematol Oncol"},{"key":"3227_CR135","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12964-025-02091-5","volume":"23","author":"L Merino-Cacho","year":"2025","unstructured":"Merino-Cacho, L., Barroso-Gomila, O., Pozo-Rodr\u00edguez, M., Muratore, V., Guinea-P\u00e9rez, C., Serrano, \u00c1., P\u00e9rez, C., Cano-L\u00f3pez, S., Urcullu, A., Azkargorta, M., et al. (2025). Cullin-RING ligase BioE3 reveals molecular-glue-induced neosubstrates and rewiring of the endogenous Cereblon ubiquitome. Cell Commun Signal 23, 101.","journal-title":"Cell Commun Signal"},{"key":"3227_CR136","doi-asserted-by":"publisher","first-page":"606","DOI":"10.3390\/cells11040606","volume":"11","author":"S Mor\u00e8","year":"2022","unstructured":"Mor\u00e8, S., Corvatta, L., Manieri, V.M., Saraceni, F., Scortechini, I., Mancini, G., Fiorentini, A., Olivieri, A., and Offidani, M. (2022). Autologous stem cell transplantation in multiple myeloma: where are we and where do we want to go? Cells 11, 606.","journal-title":"Cells"},{"key":"3227_CR137","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N.C., Anderson Jr., L.D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021). Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 384, 705\u2013716.","journal-title":"N Engl J Med"},{"key":"3227_CR138","doi-asserted-by":"publisher","first-page":"104041","DOI":"10.1016\/j.critrevonc.2023.104041","volume":"188","author":"P Neri","year":"2023","unstructured":"Neri, P., and Nijhof, I. (2023). Evidence-based mechanisms of synergy with IMiD agent-based combinations in multiple myeloma. Crit Rev Oncol Hematol 188, 104041.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3227_CR139","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1038\/leu.2015.123","volume":"29","author":"IS Nijhof","year":"2015","unstructured":"Nijhof, I.S., Groen, R.W.J., Lokhorst, H.M., van Kessel, B., Bloem, A.C., van Velzen, J., de Jong-Korlaar, R., Yuan, H., Noort, W.A., Klein, S.K., et al. (2015). Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia 29, 2039\u20132049.","journal-title":"Leukemia"},{"key":"3227_CR140","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40265-017-0841-y","volume":"78","author":"IS Nijhof","year":"2018","unstructured":"Nijhof, I.S., van de Donk, N.W.C.J., Zweegman, S., and Lokhorst, H.M. (2018). Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update. Drugs 78, 19\u201337.","journal-title":"Drugs"},{"key":"3227_CR141","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1002\/cncr.32065","volume":"125","author":"AK Nooka","year":"2019","unstructured":"Nooka, A.K., Kaufman, J.L., Hofmeister, C.C., Joseph, N.S., Heffner, T.L., Gupta, V.A., Sullivan, H.C., Neish, A.S., Dhodapkar, M.V., and Lonial, S. (2019). Daratumumab in multiple myeloma. Cancer 125, 2364\u20132382.","journal-title":"Cancer"},{"key":"3227_CR142","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1038\/s41375-023-01936-7","volume":"37","author":"EM Ocio","year":"2023","unstructured":"Ocio, E.M., Perrot, A., Bories, P., San-Miguel, J.F., Blau, I.W., Karlin, L., Martinez-Lopez, J., Wang, S.Y., Bringhen, S., Marcatti, M., et al. (2023). Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible\/with no immediate intent for autologous stem cell transplantation. Leukemia 37, 1521\u20131529.","journal-title":"Leukemia"},{"key":"3227_CR143","first-page":"275","volume":"73","author":"RH Parikh","year":"2023","unstructured":"Parikh, R.H., and Lonial, S. (2023). Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice. CA Cancer J Clin 73, 275\u2013285.","journal-title":"CA Cancer J Clin"},{"key":"3227_CR144","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1182\/blood-2018-01-828418","volume":"132","author":"A Patil","year":"2018","unstructured":"Patil, A., Manzano, M., and Gottwein, E. (2018). CK1\u03b1 and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma. Blood 132, 577\u2013586.","journal-title":"Blood"},{"key":"3227_CR145","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/s41419-021-04104-w","volume":"12","author":"S Petillo","year":"2021","unstructured":"Petillo, S., Capuano, C., Molfetta, R., Fionda, C., Mekhloufi, A., Pighi, C., Antonangeli, F., Zingoni, A., Soriani, A., Petrucci, M.T., et al. (2021). Immunomodulatory effect of NEDD8-activating enzyme inhibition in multiple myeloma: upregulation of NKG2D ligands and sensitization to natural killer cell recognition. Cell Death Dis 12, 836.","journal-title":"Cell Death Dis"},{"key":"3227_CR146","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1182\/blood.2019000050","volume":"134","author":"MJ Pont","year":"2019","unstructured":"Pont, M.J., Hill, T., Cole, G.O., Abbott, J.J., Kelliher, J., Salter, A.I., Hudecek, M., Comstock, M.L., Rajan, A., Patel, B.K.R., et al. (2019). \u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood 134, 1585\u20131597.","journal-title":"Blood"},{"key":"3227_CR147","first-page":"3065","volume":"110","author":"AJ Portuguese","year":"2025","unstructured":"Portuguese, A.J., Liang, E.C., Huang, J.J., Jeon, Y., Dima, D., Banerjee, R., Kwok, M., Cicero, K.I., Hirayama, A.V., Basom, R., et al. (2025). Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myeloma. Haematologica 110, 3065\u20133077.","journal-title":"Haematologica"},{"key":"3227_CR148","doi-asserted-by":"publisher","first-page":"895","DOI":"10.3324\/haematol.2023.283509","volume":"109","author":"L Pour","year":"2024","unstructured":"Pour, L., Szarejko, M., Bila, J., Schjesvold, F.H., Spicka, I., Maisnar, V., Jurczyszyn, A., Grudeva-Popova, Z., H\u00e1jek, R., Usenko, G., et al. (2024). Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed\/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study. Haematologica 109, 895\u2013905.","journal-title":"Haematologica"},{"key":"3227_CR149","doi-asserted-by":"publisher","first-page":"1483806","DOI":"10.3389\/fimmu.2024.1483806","volume":"15","author":"V Raimondi","year":"2024","unstructured":"Raimondi, V., Vescovini, R., Dessena, M., Donofrio, G., Storti, P., and Giuliani, N. (2024). Oncolytic viruses: a potential breakthrough immunotherapy for multiple myeloma patients. Front Immunol 15, 1483806.","journal-title":"Front Immunol"},{"key":"3227_CR150","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","volume":"13","author":"N Raje","year":"2023","unstructured":"Raje, N., Anderson, K., Einsele, H., Efebera, Y., Gay, F., Hammond, S.P., Lesokhin, A. M., Lonial, S., Ludwig, H., Moreau, P., et al. (2023). Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J 13, 116.","journal-title":"Blood Cancer J"},{"key":"3227_CR151","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M.V., Turka, A., et al. (2019). Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med 380, 1726\u20131737.","journal-title":"N Engl J Med"},{"key":"3227_CR152","doi-asserted-by":"publisher","first-page":"101147","DOI":"10.1016\/j.xcrm.2023.101147","volume":"4","author":"M Rao","year":"2023","unstructured":"Rao, M., Amouzgar, M., Harden, J.T., Lapasaran, M.G., Trickey, A., Armstrong, B., Odim, J., Debnam, T., Esquivel, C.O., Bendall, S.C., et al. (2023). High-dimensional profiling of pediatric immune responses to solid organ transplantation. Cell Rep Med 4, 101147.","journal-title":"Cell Rep Med"},{"key":"3227_CR153","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1182\/blood.2023021221","volume":"143","author":"L Rasche","year":"2024","unstructured":"Rasche, L., Hudecek, M., and Einsele, H. (2024). CAR T-cell therapy in multiple myeloma: mission accomplished? Blood 143, 305\u2013310.","journal-title":"Blood"},{"key":"3227_CR154","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","volume":"20","author":"PG Richardson","year":"2019","unstructured":"Richardson, P.G., Oriol, A., Beksac, M., Liberati, A.M., Galli, M., Schjesvold, F., Lindsay, J., Weisel, K., White, D., Facon, T., et al. (2019). Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol 20, 781\u2013794.","journal-title":"Lancet Oncol"},{"key":"3227_CR155","first-page":"2239","volume":"109","author":"PG Richardson","year":"2024","unstructured":"Richardson, P.G., Perrot, A., Miguel, J.S., Beksac, M., Spicka, I., Leleu, X., Schjesvold, F., Moreau, P., Dimopoulos, M.A., Huang, S.Y., et al. (2024). Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis. Haematologica 109, 2239\u20132249.","journal-title":"Haematologica"},{"key":"3227_CR156","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1470-2045(22)00019-5","volume":"23","author":"PG Richardson","year":"2022","unstructured":"Richardson, P.G., Perrot, A., San-Miguel, J., Beksac, M., Spicka, I., Leleu, X., Schjesvold, F., Moreau, P., Dimopoulos, M.A., Huang, J.S.Y., et al. (2022). Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol 23, 416\u2013427.","journal-title":"Lancet Oncol"},{"key":"3227_CR157","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","volume":"389","author":"PG Richardson","year":"2023","unstructured":"Richardson, P.G., Trudel, S., Popat, R., Mateos, M.V., Vangsted, A.J., Ramasamy, K., Martinez-Lopez, J., Quach, H., Orlowski, R.Z., Arnao, M., et al. (2023). Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma. N Engl J Med 389, 1009\u20131022.","journal-title":"N Engl J Med"},{"key":"3227_CR158","first-page":"2470","volume":"141","author":"C Roddie","year":"2023","unstructured":"Roddie, C., Lekakis, L.J., Marzolini, M.A.V., Ramakrishnan, A., Zhang, Y., Hu, Y., Peddareddigari, V.G.R., Khokhar, N.Z., Chen, R.W., Basilico, S., et al. (2023). Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed\/ refractory large B cell lymphoma. Blood 141, 2470\u20132482.","journal-title":"Blood"},{"key":"3227_CR159","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A.K., Manier, S., Callander, N., Costa, L.J., Vij, R., et al. (2023). Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med 388, 1002\u20131014.","journal-title":"N Engl J Med"},{"key":"3227_CR160","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13045-020-01001-1","volume":"13","author":"G Roex","year":"2020","unstructured":"Roex, G., Timmers, M., Wouters, K., Campillo-Davo, D., Flumens, D., Schroyens, W., Chu, Y., Berneman, Z.N., Lion, E., Luo, F., et al. (2020). Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. J Hematol Oncol 13, 164.","journal-title":"J Hematol Oncol"},{"key":"3227_CR161","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s41573-023-00807-1","volume":"22","author":"M Ruella","year":"2023","unstructured":"Ruella, M., Korell, F., Porazzi, P., and Maus, M.V. (2023). Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies. Nat Rev Drug Discov 22, 976\u2013995.","journal-title":"Nat Rev Drug Discov"},{"key":"3227_CR162","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3390\/cells9010167","volume":"9","author":"I Saltarella","year":"2020","unstructured":"Saltarella, I., Desantis, V., Melaccio, A., Solimando, A.G., Lamanuzzi, A., Ria, R., Storlazzi, C.T., Mariggi\u00f2, M.A., Vacca, A., and Frassanito, M.A. (2020). Mechanisms of resistance to anti-CD38 daratumumab in multiple myeloma. Cells 9, 167.","journal-title":"Cells"},{"key":"3227_CR163","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur, M.K., Fulciniti, M., Aktas Samur, A., Bazarbachi, A.H., Tai, Y.T., Prabhala, R., Alonso, A., Sperling, A.S., Campbell, T., Petrocca, F., et al. (2021). Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun 12, 868.","journal-title":"Nat Commun"},{"key":"3227_CR164","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.V., Fern\u00e1ndez de Larrea, C., Mart\u00ednez-L\u00f3pez, J., Moreau, P., Touzeau, C., et al. (2023). Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med 389, 335\u2013347.","journal-title":"N Engl J Med"},{"key":"3227_CR165","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41467-023-44237-4","volume":"15","author":"M Schr\u00f6der","year":"2024","unstructured":"Schr\u00f6der, M., Renatus, M., Liang, X., Meili, F., Zoller, T., Ferrand, S., Gauter, F., Li, X., Sigoillot, F., Gleim, S., et al. (2024). DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance. Nat Commun 15, 275.","journal-title":"Nat Commun"},{"key":"3227_CR166","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41571-019-0184-6","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah, N.N., and Fry, T.J. (2019). Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol 16, 372\u2013385.","journal-title":"Nat Rev Clin Oncol"},{"key":"3227_CR167","doi-asserted-by":"publisher","first-page":"m3176","DOI":"10.1136\/bmj.m3176","volume":"370","author":"UA Shah","year":"2020","unstructured":"Shah, U.A., and Mailankody, S. (2020). Emerging immunotherapies in multiple myeloma. BMJ 370, m3176.","journal-title":"BMJ"},{"key":"3227_CR168","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/s43018-022-00444-4","volume":"3","author":"F Shao","year":"2022","unstructured":"Shao, F., Gao, Y., Wang, W., He, H., Xiao, L., Geng, X., Xia, Y., Guo, D., Fang, J., He, J., et al. (2022). Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade. Nat Cancer 3, 1192\u20131210.","journal-title":"Nat Cancer"},{"key":"3227_CR169","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","volume":"15","author":"M Shi","year":"2024","unstructured":"Shi, M., Wang, J., Huang, H., Liu, D., Cheng, H., Wang, X., Chen, W., Yan, Z., Sang, W., Qi, K., et al. (2024). Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial. Nat Commun 15, 3371.","journal-title":"Nat Commun"},{"key":"3227_CR170","doi-asserted-by":"publisher","first-page":"e354","DOI":"10.1016\/S2352-3026(20)30098-3","volume":"7","author":"TL Shigle","year":"2020","unstructured":"Shigle, T.L., and Bashir, Q. (2020). Advancement in monoclonal antibody therapy for multiple myeloma. Lancet Haematol 7, e354\u2013e355.","journal-title":"Lancet Haematol"},{"key":"3227_CR171","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMe2307370","volume":"389","author":"J Shortt","year":"2023","unstructured":"Shortt, J. (2023). Mezigdomide and multiple myeloma. N Engl J Med 389, 1046\u20131050.","journal-title":"N Engl J Med"},{"key":"3227_CR172","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1158\/2643-3230.BCD-20-0122","volume":"1","author":"S Simon","year":"2020","unstructured":"Simon, S., and Riddell, S.R. (2020). Dual targeting with CAR T cells to limit antigen escape in multiple myeloma. Blood Cancer Discov 1, 130\u2013133.","journal-title":"Blood Cancer Discov"},{"key":"3227_CR173","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1182\/bloodadvances.2023010579","volume":"8","author":"A Spencer","year":"2024","unstructured":"Spencer, A., Moreau, P., Mateos, M.V., Goldschmidt, H., Suzuki, K., Levin, M.D., Sonneveld, P., Orlowski, R.Z., Yoon, S.S., Usmani, S.Z., et al. (2024). Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX. Blood Adv 8, 388\u2013398.","journal-title":"Blood Adv"},{"key":"3227_CR174","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner, R.C., and Sterner, R.M. (2021). CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 11, 69.","journal-title":"Blood Cancer J"},{"key":"3227_CR175","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/17460441.2024.2319672","volume":"19","author":"I Strassl","year":"2024","unstructured":"Strassl, I., and Podar, K. (2024). The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myeloma. Expert Opin Drug Discov 19, 377\u2013391.","journal-title":"Expert Opin Drug Discov"},{"key":"3227_CR176","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13045-022-01234-2","volume":"15","author":"M Swamydas","year":"2022","unstructured":"Swamydas, M., Murphy, E.V., Ignatz-Hoover, J.J., Malek, E., and Driscoll, J.J. (2022). Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma. J Hematol Oncol 15, 17.","journal-title":"J Hematol Oncol"},{"key":"3227_CR177","doi-asserted-by":"publisher","first-page":"e006119","DOI":"10.1136\/jitc-2022-006119","volume":"11","author":"J Tang","year":"2023","unstructured":"Tang, J., Sheng, J., Zhang, Q., Ji, Y., Wang, X., Zhang, J., Wu, J., Song, J., Bai, X., and Liang, T. (2023). Runx3-overexpression cooperates with ex vivo AKT inhibition to generate receptor-engineered T cells with better persistence, tumor-residency, and antitumor ability. J Immunother Cancer 11, e006119.","journal-title":"J Immunother Cancer"},{"key":"3227_CR178","doi-asserted-by":"publisher","first-page":"6960","DOI":"10.1038\/s41467-021-26951-z","volume":"12","author":"SM Tirier","year":"2021","unstructured":"Tirier, S.M., Mallm, J.P., Steiger, S., Poos, A.M., Awwad, M.H.S., Giesen, N., Casiraghi, N., Susak, H., Bauer, K., Baumann, A., et al. (2021). Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics. Nat Commun 12, 6960.","journal-title":"Nat Commun"},{"key":"3227_CR179","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1200\/JCO.19.02657","volume":"38","author":"MS Topp","year":"2020","unstructured":"Topp, M.S., Duell, J., Zugmaier, G., Attal, M., Moreau, P., Langer, C., Kr\u00f6nke, J., Facon, T., Salnikov, A.V., Lesley, R., et al. (2020). Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma. J Clin Oncol 38, 775\u2013783.","journal-title":"J Clin Oncol"},{"key":"3227_CR180","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1182\/blood.2023023597","volume":"143","author":"C Touzeau","year":"2024","unstructured":"Touzeau, C., Perrot, A., Hulin, C., Manier, S., Macro, M., Chretien, M.L., Karlin, L., Escoffre, M., Jacquet, C., Tiab, M., et al. (2024). Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma. Blood 143, 2029\u20132036.","journal-title":"Blood"},{"key":"3227_CR181","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-018-0589-1","volume":"11","author":"R Tremblay-LeMay","year":"2018","unstructured":"Tremblay-LeMay, R., Rastgoo, N., and Chang, H. (2018). Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1\/PD-L1 pathway. J Hematol Oncol 11, 46.","journal-title":"J Hematol Oncol"},{"key":"3227_CR182","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama, K., Anami, Y., Ha, S.Y.Y., and Yamazaki, C.M. (2024). Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol 21, 203\u2013223.","journal-title":"Nat Rev Clin Oncol"},{"key":"3227_CR183","doi-asserted-by":"publisher","first-page":"1697732","DOI":"10.3389\/fimmu.2025.1697732","volume":"16","author":"J Tu","year":"2025","unstructured":"Tu, J., Li, X., Zhu, Y., Li, S., Zhang, G., He, Y., Zhang, C., and Lu, Z. (2025). Framework humanization enhances GM3(Neu5Gc)-targeting CAR-T cell function by reducing tonic signaling. Front Immunol 16, 1697732.","journal-title":"Front Immunol"},{"key":"3227_CR184","doi-asserted-by":"publisher","first-page":"E146","DOI":"10.1002\/ajh.24781","volume":"92","author":"SZ Usmani","year":"2017","unstructured":"Usmani, S.Z., Diels, J., Ito, T., Mehra, M., Khan, I., and Lam, A. (2017). Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: an adjusted treatment comparison. Am J Hematol 92, E146\u2013E152.","journal-title":"Am J Hematol"},{"key":"3227_CR185","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","volume":"131","author":"NWCJ van de Donk","year":"2018","unstructured":"van de Donk, N.W.C.J., Richardson, P.G., and Malavasi, F. (2018). CD38 antibodies in multiple myeloma: back to the future. Blood 131, 13\u201329.","journal-title":"Blood"},{"key":"3227_CR186","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","volume":"8","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk, N.W.C.J., Usmani, S.Z., and Yong, K. (2021a). CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol 8, e446\u2013e461.","journal-title":"Lancet Haematol"},{"key":"3227_CR187","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk, N.W.C.J., Pawlyn, C., and Yong, K.L. (2021b). Multiple myeloma. Lancet 397, 410\u2013427.","journal-title":"Lancet"},{"key":"3227_CR188","doi-asserted-by":"publisher","first-page":"4219","DOI":"10.1158\/1078-0432.CCR-23-0132","volume":"29","author":"JJ van der Schans","year":"2023","unstructured":"van der Schans, J.J., Wang, Z., van Arkel, J., van Schaik, T., Katsarou, A., Ruiter, R., Baardemans, T., Yuan, H., de Bruijn, J., Zweegman, S., et al. (2023). Specific targeting of multiple myeloma by dual split-signaling chimeric antigen receptor T cells directed against CD38 and CD138. Clin Cancer Res 29, 4219\u20134229.","journal-title":"Clin Cancer Res"},{"key":"3227_CR189","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees, P.M., Kaufman, J.L., Laubach, J., Sborov, D.W., Reeves, B., Rodriguez, C., Chari, A., Silbermann, R., Costa, L.J., Anderson Jr, L.D., et al. (2020). Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 136, 936\u2013945.","journal-title":"Blood"},{"key":"3227_CR190","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","volume":"10","author":"PM Voorhees","year":"2023","unstructured":"Voorhees, P.M., Sborov, D.W., Laubach, J., Kaufman, J.L., Reeves, B., Rodriguez, C., Chari, A., Silbermann, R., Costa, L.J., Anderson Jr, L.D., et al. (2023). Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol 10, e825\u2013e837.","journal-title":"Lancet Haematol"},{"key":"3227_CR191","doi-asserted-by":"publisher","first-page":"6432","DOI":"10.1158\/1078-0432.CCR-21-2040","volume":"27","author":"JM Waldschmidt","year":"2021","unstructured":"Waldschmidt, J.M., Kloeber, J.A., Anand, P., Frede, J., Kokkalis, A., Dimitrova, V., Potdar, S., Nair, M.S., Vijaykumar, T., Im, N.G., et al. (2021). Single-cell profiling reveals metabolic reprogramming as a resistance mechanism in BRAF-mutated multiple myeloma. Clin Cancer Res 27, 6432\u20136444.","journal-title":"Clin Cancer Res"},{"key":"3227_CR192","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41419-023-06046-x","volume":"14","author":"H Wang","year":"2023","unstructured":"Wang, H., Pan, X., Xiang, X., Zhang, Y., Chen, J., Wen, S., Wang, J., Gao, R., Yang, J., Zhi, Y., et al. (2023). CRISPR screen identifies the role of RBBP8 in mediating unfolded protein response induced liver damage through regulating protein synthesis. Cell Death Dis 14, 531.","journal-title":"Cell Death Dis"},{"key":"3227_CR193","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40364-021-00297-6","volume":"9","author":"S Wang","year":"2021","unstructured":"Wang, S., Li, Z., and Gao, S. (2021). Key regulators of sensitivity to immunomodulatory drugs in cancer treatment. Biomark Res 9, 43.","journal-title":"Biomark Res"},{"key":"3227_CR194","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1200\/JCO.21.01676","volume":"40","author":"Y Wang","year":"2022","unstructured":"Wang, Y., Cao, J., Gu, W., Shi, M., Lan, J., Yan, Z., Jin, L., Xia, J., Ma, S., Liu, Y., et al. (2022). Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma. J Clin Oncol 40, 2246\u20132256.","journal-title":"J Clin Oncol"},{"key":"3227_CR195","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-016-0284-z","volume":"9","author":"Y Wang","year":"2016","unstructured":"Wang, Y., Sanchez, L., Siegel, D.S., and Wang, M.L. (2016). Elotuzumab for the treatment of multiple myeloma. J Hematol Oncol 9, 55.","journal-title":"J Hematol Oncol"},{"key":"3227_CR196","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1126\/science.add7574","volume":"378","author":"ER Watson","year":"2022","unstructured":"Watson, E.R., Novick, S., Matyskiela, M.E., Chamberlain, P.P., H. de la Pe\u00f1a, A., Zhu, J., Tran, E., Griffin, P.R., Wertz, I.E., and Lander, G.C. (2022). Molecular glue CELMoD compounds are regulators of cereblon conformation. Science 378, 549\u2013553.","journal-title":"Science"},{"key":"3227_CR197","doi-asserted-by":"publisher","first-page":"e20221563","DOI":"10.1084\/jem.20221563","volume":"220","author":"W Wei","year":"2023","unstructured":"Wei, W., Geer, M.J., Guo, X., Dolgalev, I., Sanjana, N.E., and Neel, B.G. (2023). Genome-wide CRISPR\/Cas9 screens reveal shared and cell-specific mechanisms of resistance to SHP2 inhibition. J Exp Med 220, e20221563.","journal-title":"J Exp Med"},{"key":"3227_CR198","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/2643-3230.BCD-23-0062","volume":"5","author":"SJ Welsh","year":"2024","unstructured":"Welsh, S.J., Barwick, B.G., Meermeier, E.W., Riggs, D.L., Shi, C.X., Zhu, Y.X., Sharik, M.E., Du, M.T., Abrego Rocha, L.D., Garbitt, V.M., et al. (2024). Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma. Blood Cancer Discov 5, 34\u201355.","journal-title":"Blood Cancer Discov"},{"key":"3227_CR199","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1200\/JCO.22.01824","volume":"41","author":"J Xia","year":"2023","unstructured":"Xia, J., Li, H., Yan, Z., Zhou, D., Wang, Y., Qi, Y., Cao, J., Li, D., Cheng, H., Sang, W., et al. (2023). Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase II trial. J Clin Oncol 41, 2583\u20132593.","journal-title":"J Clin Oncol"},{"key":"3227_CR200","doi-asserted-by":"publisher","first-page":"5376","DOI":"10.1158\/1078-0432.CCR-21-1621","volume":"27","author":"L Xing","year":"2021","unstructured":"Xing, L., Wang, S., Liu, J., Yu, T., Chen, H., Wen, K., Li, Y., Lin, L., Hsieh, P.A., Cho, S. F., et al. (2021). BCMA-specific ADC MEDI2228 and daratumumab induce synergistic myeloma cytotoxicity via IFN-driven immune responses and enhanced CD38 expression. Clin Cancer Res 27, 5376\u20135388.","journal-title":"Clin Cancer Res"},{"key":"3227_CR201","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1073\/pnas.1819745116","volume":"116","author":"J Xu","year":"2019","unstructured":"Xu, J., Chen, L.J., Yang, S.S., Sun, Y., Wu, W., Liu, Y.F., Xu, J., Zhuang, Y., Zhang, W., Weng, X.Q., et al. (2019). Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma. Proc Natl Acad Sci USA 116, 9543\u20139551.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3227_CR202","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1002\/mco2.146","volume":"3","author":"P Yang","year":"2022","unstructured":"Yang, P., Qu, Y., Wang, M., Chu, B., Chen, W., Zheng, Y., Niu, T., and Qian, Z. (2022). Pathogenesis and treatment of multiple myeloma. MedComm 3, e146.","journal-title":"MedComm"},{"key":"3227_CR203","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-22-1769","volume":"83","author":"L Yao","year":"2023","unstructured":"Yao, L., Wang, J.T., Jayasinghe, R.G., O\u2019Neal, J., Tsai, C.F., Rettig, M.P., Song, Y., Liu, R., Zhao, Y., Ibrahim, O.M., et al. (2023). Single-cell discovery and multiomic characterization of therapeutic targets in multiple myeloma. Cancer Res 83, 1214\u20131233.","journal-title":"Cancer Res"},{"key":"3227_CR204","doi-asserted-by":"publisher","first-page":"2307852","DOI":"10.1002\/advs.202307852","volume":"11","author":"Y Yu","year":"2024","unstructured":"Yu, Y., Tian, W., Grauffel, C., Lin, W., Hsieh, M., Wu, P., Lee, H., Peng, C., Lin, P., Chu, H., et al. (2024). An antibody-drug conjugate for multiple myeloma prepared by multi-arm linkers. Adv Sci 11, 2307852.","journal-title":"Adv Sci"},{"key":"3227_CR205","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1158\/2643-3230.BCD-23-0223","volume":"5","author":"S Yun","year":"2024","unstructured":"Yun, S., and Cleveland, J.L. (2024). Transcriptional plasticity drives IMiD and p300 inhibitor resistance in multiple myeloma. Blood Cancer Discov 5, 5\u20137.","journal-title":"Blood Cancer Discov"},{"key":"3227_CR206","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","volume":"11","author":"E Zah","year":"2020","unstructured":"Zah, E., Nam, E., Bhuvan, V., Tran, U., Ji, B.Y., Gosliner, S.B., Wang, X., Brown, C.E., and Chen, Y.Y. (2020). Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Nat Commun 11, 2283.","journal-title":"Nat Commun"},{"key":"3227_CR207","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","volume":"1","author":"O Zavidij","year":"2020","unstructured":"Zavidij, O., Haradhvala, N.J., Mouhieddine, T.H., Sklavenitis-Pistofidis, R., Cai, S., Reidy, M., Rahmat, M., Flaifel, A., Ferland, B., Su, N.K., et al. (2020). Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer 1, 493\u2013506.","journal-title":"Nat Cancer"},{"key":"3227_CR208","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1186\/s12967-025-06365-x","volume":"23","author":"F Zhang","year":"2025","unstructured":"Zhang, F., Du, H., Liu, K., Guo, Q., Liang, M., Shi, J., Feng, S., He, T., Lu, X., Tang, Y., et al. (2025). MUC18-Directed chimeric antigen receptor T cells for the treatment of mucosal melanoma. J Transl Med 23, 473.","journal-title":"J Transl Med"},{"key":"3227_CR209","doi-asserted-by":"publisher","first-page":"106036","DOI":"10.1016\/j.phrs.2021.106036","volume":"175","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z., Wang, T., Wang, X., Zhang, Y., Song, S., and Ma, C. (2022). Improving the ability of CAR-T cells to hit solid tumors: challenges and strategies. Pharmacol Res 175, 106036.","journal-title":"Pharmacol Res"},{"key":"3227_CR210","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-023-01489-3","volume":"16","author":"J Zhao","year":"2023","unstructured":"Zhao, J., Ren, Q., Liu, X., Guo, X., and Song, Y. (2023). Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting. J Hematol Oncol 16, 92.","journal-title":"J Hematol Oncol"},{"key":"3227_CR211","doi-asserted-by":"publisher","first-page":"e75340","DOI":"10.7554\/eLife.75340","volume":"11","author":"L Zhong","year":"2022","unstructured":"Zhong, L., Hao, P., Zhang, Q., Jiang, T., Li, H., Xiao, J., Li, C., Luo, L., Xie, C., Hu, J., et al. (2022a). Revised International Staging System (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myeloma (MM). eLife 11, e75340.","journal-title":"eLife"},{"key":"3227_CR212","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s11427-021-2097-1","volume":"65","author":"L Zhong","year":"2022","unstructured":"Zhong, L., Yang, X., Zhou, Y., Xiao, J., Li, H., Tao, J., Xi, Q., Chu, C., Li, C., Yang, X., et al. (2022b). Exploring the R-ISS stage-specific regular networks in the progression of multiple myeloma at single-cell resolution. Sci China Life Sci 65, 1811\u20131823.","journal-title":"Sci China Life Sci"},{"key":"3227_CR213","doi-asserted-by":"publisher","first-page":"102199","DOI":"10.1016\/j.xcrm.2025.102199","volume":"6","author":"Z Zhou","year":"2025","unstructured":"Zhou, Z., Chen, S., Zhao, J., Du, X., Yin, H., Zhou, C., Hu, H., Yu, Y., Zhu, Y., and Yao, H. (2025). EGFR TKIs suppress MUC1 glycosylation through the PI3K\/AKT\/SP1\/C1GALT1 pathway to enhance TnMUC1 CAR-T efficacy in EGFR-mutant NSCLC. Cell Rep Med 6, 102199.","journal-title":"Cell Rep Med"}],"container-title":["Science China Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-025-3227-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11427-025-3227-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-025-3227-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:02:05Z","timestamp":1784908925000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11427-025-3227-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":213,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3227"],"URL":"https:\/\/doi.org\/10.1007\/s11427-025-3227-0","relation":{},"ISSN":["1674-7305","1869-1889"],"issn-type":[{"value":"1674-7305","type":"print"},{"value":"1869-1889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance and ethics"}}]}}